Home > Camille Carroll, MDS 2020 – Results of the PD STAT Study
Parkinson's Disease

Camille Carroll, MDS 2020 – Results of the PD STAT Study

Published Online: October 16th 2020

It was a pleasure to speak with Camille Carroll (University of Plymouth, Plymouth, UK) about her late-breaking presentation entitled: Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): results of a double-blind, randomised, placebo-controlled futility study. ClinicalTrials.gov Identifier: NCT02787590.


  1. What was the scientific rationale for investigating simvastatin as a neuroprotective treatment for Parkinson’s disease (PD)? (0:06)
  2. Could you tell us a little about the aims and design of the PD STAT trial? (1:48)
  3. Did COVID-19 pose any challenge to the study? (3:25)
  4. What were the main findings of this study? (6:23)
  5. Why do you think that simvastatin was not effective in slowing the rate of progression of PD? (6:05)
  6. What other potentially disease-modifying agents are being investigated? (8:11)

Disclosures: Dr Carroll is the study director and reports receiving study funding from the Cure Parkinson’s Trust and JP Moulton Charitable Foundation.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.

Share this Video
Related Videos In Parkinson's Disease
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar